Get the Stockscreener App
7.44
9.16%
-0.75
Immunitybio Inc stock is traded at $7.44, with a volume of 16.86M.
It is down -9.16% in the last 24 hours and up +0.34% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$8.19
Open:
$8.16
24h Volume:
16.86M
Relative Volume:
0.56
Market Cap:
$7.68B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-19.09
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-3.38%
1M Performance:
+0.34%
6M Performance:
+201.21%
1Y Performance:
+176.58%
1-Day Range:
$7.41
$8.28
1-Week Range:
$7.41
$8.56
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.44 | 8.46B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 110.67B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 80.98B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 49.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 41.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.28B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - The Daily Tribune News
Does Saudi ANKTIVA Launch Signal a New Phase in ImmunityBio’s (IBRX) Commercial Strategy? - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Market Moves and Biotech Sector Signals - Kalkine Media
ImmunityBio (NASDAQ:IBRX) Stock Price Down 6.2%Time to Sell? - MarketBeat
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit - The Globe and Mail
IBRX Stock Slides As FDA Warning Letter Sparks Class Actions - StocksToTrade
IBRX Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ImmunityBio, Inc. (IBRX) Expands ANKTIVA Access With First Commercial Use in Saudi Arabia - Insider Monkey
IBRX DEADLINE: The Gross Law Firm Reminds ImmunityBio, Inc. - GlobeNewswire
IBRX garners retail attention on positive update in immunotherapy for lung cancer patients - MSN
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit- Hagens Berman - PR Newswire
ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline - The Globe and Mail
ROSEN, NATIONAL TRIAL LAWYERS, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - TMX Newsfile
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
IBRX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion LawsImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Securities Class Action Lawsuit Filed Against ImmunityBio, Inc. (IBRX) - GlobeNewswire
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - GlobeNewswire Inc.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securi - GuruFocus
ROSEN, A LONGSTANDING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, A LONGSTANDING LAW FIRM, Encourages ImmunityBio, - GlobeNewswire
ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline - NewMediaWire
Best Biotech Stocks To Watch TodayApril 22nd - MarketBeat
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
IBRX Investor Alert: ImmunityBio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After FDA Allegedly Exposed Misleading Claims: Levi & Korsinsky - PR Newswire
ANKTIVA Becomes Available in Saudi Arabia, Expanding Cancer Treatment AccessImmunityBio - Oncodaily
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
ImmunityBio, Inc. Securities Fraud Class Action Result of - GlobeNewswire
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX - FinancialContent
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Jim Cramer Suggests Waiting for Clarity on ImmunityBio Before Taking a “Hard Look” - Insider Monkey
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - Morningstar
IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline - TMX Newsfile
IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
ImmunityBio Stock Rises As ANKTIVA Launches in Saudi Arabia - Benzinga
IBRX Stock Has Quadrupled This Year – And Its Breakout Cancer Drug Has Hit A New Market - Stocktwits
IBRX Shareholder Alert: May 26, 2026 Lead Plaintiff Deadline in ImmunityBio, Inc. Securities Class Action Lawsuit — The Gross Law Firm - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
ImmunityBio’s Anktiva launches commercially in Saudi Arabia - Investing.com
ImmunityBio’s Anktiva launches commercially in Saudi Arabia By Investing.com - Investing.com UK
ImmunityBio, Inc. (NASDAQ: IBRX) recently announced that its innovative drug Anktiva® has officially entered the Saudi Arabian market, offering new treatment options for local patients with bladder cancer and lung cancer. - Bitget
ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership - ImmunityBio
ImmunityBio (IBRX) Is Up 12.3% After 168% Surge In Q1 2026 Preliminary RevenueWhat's Changed - simplywall.st
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for - GuruFocus
IBRX Stock Extends Rally: Founder Flags Fresh Bull Case For Anktiva On Breast Cancer Immune Signal - Stocktwits
ImmunityBio, Inc. (IBRX) posts strong preliminary Q1 sales on ANKTIVA momentum - MSN
Deadline Approaching for Investors of ImmunityBio, Inc. (NASDAQ: IBRX)Contact Kaplan Fox Before May 26, 2026 - NewMediaWire
ImmunityBio Stock Fell After FDA Letter, Derivative Suit Says - Law360
IBRX Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
ImmunityBio Inc stock (US45258J1025): Is its immunotherapy pipeline strong enough to unlock new upsi - AD HOC NEWS
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.01%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):